Immunotherapies with immune checkpoint inhibitors, such as PD-1, PD-L1, and CTLA-4 inhibitors, have demonstrated promising survival advantages in metastatic melanoma, metastatic renal cancer, and non-small cell lung cancer for the past few years [51–53]. This evidence concerns the gene CTLA4 and metastatic melanoma.